The study will be conducted as a 12 week, open-label trial, and will include seven one-hour appointments, with the first appointment lasting two hours.  Participants will be given Escitalopram (trade name Lexapro), which is a drug approved for treatment of depression.  The study will examine whether depression is suppressed with medication treatment, as well as if measures of grief improve.

           

The study is looking for 30 bereaved adults ages 18 and up, who suffer from depression brought on in the bereavement period following the loss of a parent, sibling, spouse/significant other, or child.  

 

            For more information please contact:  272-8288 or 272-4444.